Valuation: Monopar Therapeutics Inc.

Market Cap 587M 514M 474M 443M 834M 55.52B 853M 5.7B 2.2B 27.39B 2.21B 2.16B 95.09B P/E 2026 *
-38x
P/E 2027 * -25.2x
Enterprise Value 469M 410M 378M 354M 666M 44.31B 681M 4.55B 1.76B 21.86B 1.76B 1.72B 75.9B EV / Sales 2026 *
-
EV / Sales 2027 * 30.2x
Free-Float
76.77%
Yield 2026 *
-
Yield 2027 * -
06-29 Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell 2000 Value Benchmark CI
06-29 Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index CI
06-23 Monopar Therapeutics Inc. Elects Nicole Sweeny as Director CI
06-01 Monopar Therapeutics Presents Phase 2 Alxn1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients At Easl 2026 CI
05-20 Monopar Reports Publication of Phase 2 ALXN1840 Trial Data in Wilson Disease MT
05-20 Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease CI
05-15 Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-20 Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic Symptoms CI
03-27 Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-02 Monopar expands leadership team with appointment of seasoned biopharma executive Susan Rodriguez as chief commercial and strategy officer RE
03-02 Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026 CI
01-09 Morgan Stanley Initiates Coverage on Monopar Therapeutics With Overweight Rating, $115 Price Target MT
12-20 Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing MT
1 day+7.85%
1 week+40.15%
Current month+45.39%
1 month+46.76%
3 months+74.79%
6 months+37.50%
Current year+44.81%
1 week 68.21
Extreme 68.21
95.75
1 month 57.7
Extreme 57.7
95.75
Current year 50.07
Extreme 50.07
95.75
1 year 29.18
Extreme 29.18
105
3 years 1.37
Extreme 1.3695
105
5 years 1.37
Extreme 1.3695
105
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
03-31Fiscal year

Chief Operating Officer

8,599 0.1287%
03-31Fiscal year

Founder

15,436 0.2310%
03-02Free

Executive/Senior Manager

48,728 0.7292%
Change 5-day change 1-year change 3-year change Capi.($)
+7.85%+40.15%+181.43%+2,049.34% 587M
+0.94%+8.20%-4.77%+1.97% 46.2B
+5.79%+18.18%+421.86%+619.81% 38.71B
+1.12%+15.21%+22.74%-11.83% 31.9B
+3.61%+7.34%+20.23%+61.23% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
+1.13%+14.24% - - 16.2B
+1.45%+16.19%+72.11%+133.41% 15.05B
-1.13%+9.05%+12.03%+18.95% 13.74B
-0.60%+8.86%+102.74%+97.53% 13.42B
Average +2.04%+12.54%+94.00%+333.97% 23.07B
Weighted average by Cap. +1.42%+10.12%+96.13%+145.60%

Financials

2026 *2027 *
Net sales - 15.7M 13.75M 12.68M 11.85M 22.31M 1.48B 22.8M 152M 58.93M 732M 58.97M 57.68M 2.54B
Net income -20.16M -17.65M -16.27M -15.21M -28.64M -1.91B -29.27M -196M -75.65M -940M -75.71M -74.05M -3.26B -35.92M -31.44M -28.99M -27.1M -51.02M -3.4B -52.15M -349M -135M -1.68B -135M -132M -5.82B
Net Debt -119M -104M -95.7M -89.46M -168M -11.21B -172M -1.15B -445M -5.53B -445M -435M -19.2B -112M -98.33M -90.68M -84.77M -160M -10.62B -163M -1.09B -422M -5.24B -422M -413M -18.19B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
29/06/26 $94.34 +7.60% 119,867
26/06/26 $87.68 +0.06% 310,268
25/06/26 $87.63 -1.53% 203,061
24/06/26 $88.99 +8.83% 300,288
23/06/26 $81.77 +19.09% 278,172
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
87.68USD
Average target price
112.62USD
Spread / Average Target
+28.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock